803 related articles for article (PubMed ID: 25046163)
1. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
[TBL] [Abstract][Full Text] [Related]
2. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
[TBL] [Abstract][Full Text] [Related]
3. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
[TBL] [Abstract][Full Text] [Related]
4. Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of the Viral Genome to Assembly Sites.
Boson B; Denolly S; Turlure F; Chamot C; Dreux M; Cosset FL
Gastroenterology; 2017 Mar; 152(4):895-907.e14. PubMed ID: 27932311
[TBL] [Abstract][Full Text] [Related]
5. NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.
Reghellin V; Donnici L; Fenu S; Berno V; Calabrese V; Pagani M; Abrignani S; Peri F; De Francesco R; Neddermann P
Antimicrob Agents Chemother; 2014 Dec; 58(12):7128-40. PubMed ID: 25224012
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
Madan V; Paul D; Lohmann V; Bartenschlager R
Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
[TBL] [Abstract][Full Text] [Related]
8. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Friborg J; Levine S; Chen C; Sheaffer AK; Chaniewski S; Voss S; Lemm JA; McPhee F
Antimicrob Agents Chemother; 2013 Mar; 57(3):1312-22. PubMed ID: 23274666
[TBL] [Abstract][Full Text] [Related]
9. HCV NS5A inhibitors disrupt replication factory formation: a novel mechanism of antiviral action.
Eyre NS; Beard MR
Gastroenterology; 2014 Nov; 147(5):959-62. PubMed ID: 25265576
[No Abstract] [Full Text] [Related]
10. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
[TBL] [Abstract][Full Text] [Related]
11. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
[TBL] [Abstract][Full Text] [Related]
12. A Refined Model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes.
Barakat KH; Anwar-Mohamed A; Tuszynski JA; Robins MJ; Tyrrell DL; Houghton M
J Chem Inf Model; 2015 Feb; 55(2):362-73. PubMed ID: 24730573
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Activity of Combined NS5A Inhibitors.
O'Boyle DR; Nower PT; Gao M; Fridell R; Wang C; Hewawasam P; Lopez O; Tu Y; Meanwell NA; Belema M; Roberts SB; Cockett M; Sun JH
Antimicrob Agents Chemother; 2015 Dec; 60(3):1573-83. PubMed ID: 26711745
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus NS5A inhibitor daclatasvir allosterically impairs NS4B-involved protein-protein interactions within the viral replicase and disrupts the replicase quaternary structure in a replicase assembly surrogate system.
Zhang Y; Zou J; Zhao X; Yuan Z; Yi Z
J Gen Virol; 2019 Jan; 100(1):69-83. PubMed ID: 30516462
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P
J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
Gottwein JM; Jensen SB; Li YP; Ghanem L; Scheel TK; Serre SB; Mikkelsen L; Bukh J
Antimicrob Agents Chemother; 2013 Mar; 57(3):1291-303. PubMed ID: 23274664
[TBL] [Abstract][Full Text] [Related]
17. Multi-scale model for hepatitis C viral load kinetics under treatment with direct acting antivirals.
Clausznitzer D; Harnisch J; Kaderali L
Virus Res; 2016 Jun; 218():96-101. PubMed ID: 26409026
[TBL] [Abstract][Full Text] [Related]
18. A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry.
Ahmed M; Pal A; Houghton M; Barakat K
ACS Infect Dis; 2016 Nov; 2(11):872-881. PubMed ID: 27933783
[TBL] [Abstract][Full Text] [Related]
19. A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
Fernandes Campos GR; Ward J; Chen S; Bittar C; Vilela Rodrigues JP; Martinelli ALC; Souza FF; Pereira LRL; Rahal P; Harris M
J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33141008
[TBL] [Abstract][Full Text] [Related]
20. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
